Erste Asset Management Investment Blog

200 results for the topic "Equities"

ARTICLES IN THE TOPIC “Equities”

How can I as an investor benefit optimally from structural changes?
How can I as an investor benefit optimally from structural changes?
(c) pexels

How can I as an investor benefit optimally from structural changes?

Megatrends are long-term developments that not only change the financial markets, but also global economic and social life. As an investor, you can benefit from these trends, especially with a long-term investment horizon, provided you are aware of the risks and opportunities of such a strategy. Find out which structural changes could shape the markets in the future and thus offer opportunities for investors in the blog post.

Biotechnology shares ready to stage a comeback?
Biotechnology shares ready to stage a comeback?
(c) pexels.com

Biotechnology shares ready to stage a comeback?

In the first half of 2023, growth shares – and as such, also the biotechnology sector – came under pressure as investors were pivoting towards value shares. But the signs are changing. The possible high in interest rates in Europe and the USA could boost biotech shares again, as ERSTE STOCK BIOTEC fund manager Harald Kober explains in an interview.

Environmental equities – a good time to invest?
Environmental equities – a good time to invest?

Environmental equities – a good time to invest?

The sharp rise in interest rates is weighing more heavily on environmental and renewable energy equities than on assets from other sectors. Clemens Klein, fund manager of ERSTE WWF STOCK ENVIRONMENT, explains in an interview why this is the case, why environmental shares remain very attractive, and why this could even be a good time to enter the market.

Miracle drug semaglutide: slim by injection
Miracle drug semaglutide: slim by injection
(c) unsplash

Miracle drug semaglutide: slim by injection

Originally, the Danish company Novo Nordisk wanted to develop Semaglutid as a drug for diabetes 2 patients. However, the appetite-reducing effect of the drug soon became apparent, making semaglutide a miracle cure for obesity. While Novo Nordisk’s share price has risen significantly since then, possible side effects of the drug are now also being examined.